Will HIV prevention get where it’s needed?
By 
Phillip Broadwith2025-07-08T13:54:00
Gilead and its partners’ efforts to distribute generic lenacapavir could be derailed by cuts in international aid budgets
US approval of Gilead’s six-month HIV preventive injection, Yeztugo (lenacapavir), marks a significant advance in the global struggle against HIV–Aids. Two injections a year to provide near-total protection from infection is a huge step up in terms of both effectiveness and ease-of-administration, compared to daily tablet forms of pre-exposure prophylaxis (PrEP).